TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05656079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamid
Description: Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study: NCT06467279

Intervention type: DEVICE
Intervention: Target Controlled İnfusion
Description: TCI (Target-Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.

Intervention type: DRUG
Intervention: Inhalation anesthetic
Description: In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
Study: NCT05656079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study: NCT05443269

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jump Start Nutritional Program
Description: Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
Study: NCT05556343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days
Study: NCT04798482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
Study: NCT05833152

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: To observe the postoperative functional outcome of patients with knee extension lag at different angles

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: To observe the postoperative functional outcome of patients with knee extension lag at different angles

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: To observe the postoperative functional outcome of patients with knee extension lag at different angles

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: To observe the postoperative functional outcome of patients with knee extension lag at different angles
Study: NCT05385848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-rich Plasma (PRP) Injection
Description: PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
Study: NCT05776680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: 60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
Study: NCT06395870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LUCAR-G39D cells product
Description: Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
Study: NCT04762459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m²) Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
Study: NCT04729465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol
Study: NCT05094050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Continuous Subcutaneous Infusion (CSCI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Continuous Subcutaneous Infusion (CSCI)
Study: NCT04729465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: Bispectral Index Monitor
Study: NCT05009732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918
Description: 300mg once daily orally
Study: NCT05047159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy
Description: Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT
Description: The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MST
Description: A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy
Description: There is no restriction on the choice of therapeutic drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy
Description: There is no restriction on the choice of therapeutic drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy
Description: There is no restriction on the choice of therapeutic drugs.
Study: NCT06484738

Intervention type: OTHER
Intervention: transcriptomic analysis
Description: to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq

Intervention type: OTHER
Intervention: transcriptomic analysis
Description: to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq
Study: NCT04311502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ)
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ)
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Administered orally once daily
Study: NCT05009732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Local standard of care per written policies or guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Local standard of care per written policies or guidelines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study: NCT06269809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary clipping of the uterine arteries and the utero-ovarian ligmants.
Description: Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No temporary clipping of the uterine arteries and the utero-ovarian ligmants.
Description: Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
Study: NCT06148545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemental iron
Description: Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemental iron and Vit D
Description: Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
Study: NCT04311502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid (INH)
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Description: Administered based on weight orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide (PZA)
Description: Administered based on weight orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Description: Administered based on weight orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol (EMB)
Description: Administered based on weight orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol (EMB)
Description: Administered based on weight orally once daily
Study: NCT04979884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
Study: NCT04311502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol (EMB)
Description: Administered based on weight orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin (RIF)
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF)
Description: Administered orally once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Description: All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine (vitamin B6)
Description: All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
Study: NCT04979884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
Study: NCT04303702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue Oxytocin
Description: The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
Study: NCT04311502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Description: All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
Study: NCT04303702

Intervention type: OTHER
Group type: OTHER
Intervention: Discontinue Oxytocin
Description: Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
Study: NCT05666830

Intervention type: DEVICE
Intervention: Lando® artificial dermal regeneration matrix
Description: Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
Study: NCT05504499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interspinous Fusion
Description: The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
Study: NCT05152602

Intervention type: PROCEDURE
Intervention: Bilateral Erector spinae plane block
Description: Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level

Intervention type: PROCEDURE
Intervention: Unilateral Erector spinae plane block
Description: Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
Study: NCT05597384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal cancer resection
Description: This is one of the routine procedures used for colorectal cancer resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colorectal cancer resection
Description: This is one of the routine procedures used for colorectal cancer resection.
Study: NCT06392711

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells (MSC) Dose Level 0
Description: 10 (8-12) x 10\^6 MSCs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells (MSC) Dose Level 0
Description: 10 (8-12) x 10\^6 MSCs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells (MSC) Dose Level 0
Description: 10 (8-12) x 10\^6 MSCs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells (MSC) Dose Level 1
Description: 20 (16-24) x 10\^6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells (MSC) Dose Level 1
Description: 20 (16-24) x 10\^6
Study: NCT05394896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUMEN (Edwards Lifesciences, Irvine, USA)
Description: ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Blood Pressure
Description: Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
Study: NCT06479668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Task
Description: Specify details not covered in associated Arm Description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Task
Description: Specify details not covered in associated Arm Description.
Study: NCT05047159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy
Description: There is no restriction on the choice of therapeutic drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug therapy
Description: There is no restriction on the choice of therapeutic drugs.
Study: NCT03700788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 2% Chorhexidine (intracranial; remains in canal until removal at next visit)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
Study: NCT05127421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream 1.5% applied twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream 1.5% applied twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle cream applied twice a day (BID) to affected areas
Study: NCT06402812

Intervention type: OTHER
Intervention: Interview
Description: A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.

Intervention type: OTHER
Intervention: Interview
Description: A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
Study: NCT05271396

Intervention type: OTHER
Intervention: Clinical Assessment
Description: The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.

Intervention type: OTHER
Intervention: Clinical Assessment
Description: The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
Study: NCT06029205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious Awareness-Based Educatıon
Description: The effect of Conscious Awareness-Based Education on nurses

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stress coping training
Description: The effect of stress coping training on nurses
Study: NCT05040776

Intervention type: DRUG
Group type: OTHER
Intervention: EP-7041 Injection
Description: EP-7041 infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP-7041 Injection
Description: EP-7041 infusion
Study: NCT05589909

Intervention type: DIAGNOSTIC_TEST
Intervention: IL27, PCT, CRP, Blood culture
Description: magnetic bead multiplex platform

Intervention type: DIAGNOSTIC_TEST
Intervention: IL27, PCT, CRP, Blood culture
Description: magnetic bead multiplex platform
Study: NCT05500157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aspiration sclerotherapy versus laparoscopic fenestration
Description: See arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aspiration sclerotherapy versus laparoscopic fenestration
Description: See arm description